Global Kinetics to partner with uMotif to develop technology platform for Parkinson’s disease


Australian biotechnology company Global Kinetics has entered into a new partnership with uMotif to create a data capture platform for further treatment development and understanding of Parkinson's disease.

Both the companies will use their proprietary products to offer a proven and easy-to-use data capture platform which will support clinical and commercial phases of development in order to evaluate and demonstrate medications, devices and services for Parkinson's disease.

Global Kinetics president and CEO Timothy Still said: "This exciting partnership with uMotif represents a significant strategic move for us.

"I am confident that this partnership will provide a useful tool for those working to develop new therapies, disease modifying treatments and even a cure for Parkinson's."

“Responding to the needs of commercial sponsors for high quality data and systems to support both traditional and innovative trial designs, we have developed an unparalleled integrated offer with uMotif.

“I am confident that this partnership will provide a useful tool for those working to develop new therapies, disease modifying treatments and even a cure for Parkinson's."

Global Kinetics will use its Parkinson's KinetiGraph (PKG) system consisting of the PKG Data Logger and uses cloud-based proprietary algorithms to continuously record movement symptoms such as bradykinesia, dyskinesia, tremor and relates those to medication timing, sleep and exercise.

Worn like a watch, the PKG Data Logger automatically collects data from the movement of the patient which is then used to create a graphical report of the patient’s movement pattern.

uMotif will use its mobile and web platform to electronically record information ranging from patient reported data such as e-consent, patient reported outcomes (ePRO) to clinical outcomes assessments (eCOA), diaries and symptom tracking.